Vascular endothelial growth factors in retinal and choroidal neovascular diseases
- PMID: 21284527
- DOI: 10.3109/07853890.2010.532150
Vascular endothelial growth factors in retinal and choroidal neovascular diseases
Abstract
Angiogenesis, or neovascularization, refers to development of new vessels from pre-existing vasculature. Retinal and choroidal neovascularization leads to oedema, haemorrhages, and fibrosis, causing visual impairment and blindness. In multiple studies, vascular endothelial growth factor (VEGF) has been shown to be the most important factor in ocular angiogenesis. Recently discovered anti-VEGF treatments have revolutionized the therapy of neovascular diseases in the eye. These agents have been shown not just to stop the angiogenic process and maintain visual acuity but also improve vision in a great proportion of patients at least during a 2-year follow-up. However, there are also problems with these agents and their delivery regimens, and new therapeutic strategies are needed. This review summarizes the most important growth factors participating in the angiogenic process in the retina and the choroid, diseases where angiogenesis plays the most devastating part causing visual impairment, as well as current antiangiogenic treatments for these diseases.
Similar articles
-
VEGF is clearly an exciting point of attack in the treatment of neovascular diseases of the retina and choroid.Ophthalmologica. 2012;227 Suppl 1:1. Ophthalmologica. 2012. PMID: 22645747 No abstract available.
-
Systemic rapamycin inhibits retinal and choroidal neovascularization in mice.Mol Vis. 2004 Dec 22;10:964-72. Mol Vis. 2004. PMID: 15623986
-
Current and investigational pharmacotherapeutic approaches for modulating retinal angiogenesis.Expert Rev Clin Pharmacol. 2014 May;7(3):375-91. doi: 10.1586/17512433.2014.890047. Epub 2014 Mar 3. Expert Rev Clin Pharmacol. 2014. PMID: 24580084 Review.
-
[Experience with vascular endothelial growth factor inhibitors used in ophthalmologic care].Vestn Oftalmol. 2007 Sep-Oct;123(5):54-6, preceding 56. Vestn Oftalmol. 2007. PMID: 18078062 Review. Russian. No abstract available.
-
Ocular neovascularization: Implication of endogenous angiogenic inhibitors and potential therapy.Prog Retin Eye Res. 2007 Jan;26(1):1-37. doi: 10.1016/j.preteyeres.2006.09.002. Epub 2006 Oct 30. Prog Retin Eye Res. 2007. PMID: 17074526 Review.
Cited by
-
Molecular responses of choroidal endothelial cells to elastin derived peptides through the elastin-binding protein (GLB1).Matrix Biol. 2012 Mar;31(2):113-9. doi: 10.1016/j.matbio.2011.11.003. Epub 2011 Dec 2. Matrix Biol. 2012. PMID: 22178079 Free PMC article.
-
Role of Angiopoietins and Tie-2 in Diabetic Retinopathy.Electron Physician. 2017 Aug 25;9(8):5031-5035. doi: 10.19082/5031. eCollection 2017 Aug. Electron Physician. 2017. PMID: 28979738 Free PMC article.
-
CAMKII as a therapeutic target for growth factor-induced retinal and choroidal neovascularization.JCI Insight. 2019 Mar 21;4(6):e122442. doi: 10.1172/jci.insight.122442. eCollection 2019 Mar 21. JCI Insight. 2019. PMID: 30721154 Free PMC article.
-
Notch signaling in ocular vasculature development and diseases.Mol Med. 2012 Feb 10;18(1):47-55. doi: 10.2119/molmed.2011.00256. Mol Med. 2012. PMID: 21989947 Free PMC article. Review.
-
Effects of laser photocoagulation on serum angiopoietin-1, angiopoietin-2, angiopoietin-1/angiopoietin-2 ratio, and soluble angiopoietin receptor Tie-2 levels in type 2 diabetic patients with proliferative diabetic retinopathy.Int J Ophthalmol. 2014 Aug 18;7(4):648-53. doi: 10.3980/j.issn.2222-3959.2014.04.11. eCollection 2014. Int J Ophthalmol. 2014. PMID: 25161936 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
